New Migraine Drugs Can Cut Down Attacks Significantly

New Migraine Drugs Can Cut Down Attacks Significantly

Study results published Wednesday in the New England Journal of Medicine show that fremanezumab reduced the number of days patients experience headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly treatment. The drugs work by interfering with a substance involved in modifying nerve signaling and progression of pain and symptoms.

"If approved, this treatment would provide physicians with an important new tool to help prevent migraine, reduce a patient's migraine load, and potentially help patients return to normal" says Dr. Silberstein.

Researchers at Thomas Jefferson University Hospital may be nearing a breakthrough in the treatment of chronic migraines, a debilitating condition the World Health Organization estimates affects between 127 and 300 million people around the world.

Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.

There is fresh hope for millions of people who suffer with migraines on a regular basis as a top research team in the United Kingdom believe they may have developed a drug that can relieve pain and cut the duration of an attack. These excruciating headaches can often render people unable to perform simple tasks or even hold a conversation.

The trial, called Strive, compared patients taking erenumab for six months with others given a non-active placebo dummy drug.

More news: Twitter employee who deactivated Trump account: 'I feel like Pablo Escobar'

The first antibody, erenumab, is developed by Novartis and trialed on 955 patients that experienced episodic migraines.

The number of days they suffered migraines each month dropped by three to four in the drug groups and almost two in the placebo group.

The 140mg group had a 3.7-day reduction in monthly migraine days vs. a 3.2-day reduction for the 70mg dose group and a 1.8-day reduction for the placebo group. "I have three kids, so for me it meant having more days when I was able to live my everyday life, cook a meal at home, go to events at school".

With erenumab tested on episodic migraines and fremanezumab tested on chronic, it's clear that these antibody injections have a significant impact on headaches, regardless of the frequency of occurrence.

Overall, erenumab was found to be well tolerated with its safety profile on par with placebo during the trial, and also with the safety data recorded throughout the entire clinical program of the drug.